Continuing our series on Kaizen in cell therapy, we now switch both angles and companies to explore a different round early stage developments.

It was clear at ASH that to some, these were perceived as a head scratcher, while for others they were considered the best thing since sliced bread in the niche, so opinions on the controversy clearly differ quite broadly!

What’s the skinny then – and why does it all matter?

Curious to learn more?

To continue reading our latest highlights on oncology new product development including expert commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by